Abstract 107P
Background
Tumor stroma consists of a complex network of safeguards for tumor proliferation. Tumour stromal imaging using fibroblast-activated protein-tagged radionuclide provides a metabolic-radiological quantum of tumor stromal content. Tumors rich in stroma have been traditionally associated with poorer disease-free outcomes. Our study correlates between standard uptake values (SUV) in fibroblast imaging to tumor stromal ratio evaluated pathologically and the response to radiation therapy in locally advanced carcinoma rectum.
Methods
50 patients of carcinoma Rectum with all patients having undergone cancer associated Fibroblast PET CT scan prior to starting neoadjuvant chemoradiation. Tumors having SUV max > 10 were considered as High. Metabolic activity in tumor site was compared to Tumor stromal ratio and response to radiation was evaluated in histopathological report. Patients were classified into High TSR (<50% Stromal content) and Low Tumor Stroma Ratio (>50% Stromal content).
Results
7 patients who had complete pathological response all had high TSR and SUV mean 20.4. 34 patients had <50% residual disease 67% had high TSR and SUV mean 17.6 and 34% had low TSR and SUV mean of 21.44. 9 patients had >50% residual disease had 77% low TSR and high SUV mean 25.11(Range- 9.51-92.33). Patients with both Low TSR [ >50% stromal content] and SUV Max > 10 have poor pathological response compared to patients with low TSR. In the low stromal content irrespective of SUV the local control was good. Table: 107P
High TSR | Low TSR | High SUV | Low SUV | |
Complete response | 7(32%) | 0 | 4(15.4%) | 3(12.5%) |
<50% Residual disease | 23(71.8%) | 11(61%) | 14(53.8%) | 20(83.3%) |
>50% Residual disease | 2(6.2%) | 7(39%) | 8(30.8%) | 1(4.2%) |
Conclusions
High Tumor Stromal Ratio showed better complete and partial response to neoadjuvant chemoradiation in locally advanced carcinoma rectum. Tumors with high stromal content were observed to have higher SUV values in fibroblast stromal imaging and the same were also more commonly associated with suboptimal response. The need for dose escalation for the same has to be explored for better tumor control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract